Indication: Farxiga is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Insight:

Dosing: The recommended starting dose is 5 mg once daily, taken in the morning, with or without food.
Dosage form: Tablets 5 mg and 10 mg.
Adverse events (AEs): The most common AEs associated with dapagliflozin(5% or greater incidence) were female genital mycotic infections, nasopharyngitis, and urinary tract infections.
Mechanism of action: Dapagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, dapagliflozin reduces reabsorption of filtered glucose, lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.
Manufacturer: AstraZeneca

Sources:

label (fda.gov)

farxiga image - Google Search